Ironwood Pharmaceuticals Inc (IRWD)

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, holding shared voting and dispositive power. Steven Boyd, as the managing member of Armistice Capital, is also considered a beneficial owner.

State Street Corporation has disclosed a 5.4% stake in Ironwood Pharmaceuticals common stock through a passive Schedule 13G filing. The investment manager beneficially owns 8,809,601 shares, primarily with shared voting and dispositive power through its subsidiaries. This significant ownership makes State Street a key institutional holder in Ironwood.

Ironwood Pharmaceuticals reported strong second-quarter 2026 results, leading the company to raise its full-year financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. The company also announced the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure (SBS-IF), aiming for it to be the first long-acting GLP-2 analog on the market. These achievements are attributed to strong LINZESS performance, including improved net price and prescription demand growth, and strategic advancements in its pipeline.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares. The filing specifies that while various clients may benefit from dividends or sale proceeds, no individual client's interest exceeds five percent of Ironwood's outstanding common shares.

The article provides financial data specifically focusing on the Return on Assets (%) for Ironwood Pharmaceuticals, Inc. Class A, traded under the symbol I76 on the Hamburg Stock Exchange. It indicates historical values and changes for this metric, noting that the market is currently closed with no trades.